This site is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.
Dr. Martin Rabel, a Senior Field Application Scientist at Precision NanoSystems, discusses how to accelerate the next generation of transformative medicines. Building on the success of the COVID-19 mRNA vaccine, lipid nanoparticles (LNPs) offer safe and effective ways to deliver nucleic acids enabling novel vaccines, cell and gene therapies.
